Frederick H. Rein

Fred Rein is a globally-minded, tech-focused attorney.  He is licensed to practice law in New York and California as well as registered to practice before the United States Patent and Trademark Office.

After clerking in federal court in Los Angeles, Mr. Rein returned to New York City where he practiced at Kenyon & Kenyon, an intellectual property law firm.

Subsequently, he joined Goodwin Procter where he helped establish Goodwin's intellectual property litigation group in New York.

Mr. Rein served two terms as Chair of the American Intellectual Property Law Association’s Israel Committee.  He also previously served on the New York City Bar Association’s Patents Committee and Foreign & Comparative Law Committee.

Mr. Rein is designated as a Certified Information Privacy Manager (CIPM), Certified Information Privacy Professional - Europe (CIPP/E), Certified Information Privacy Professional - United States (CIPP/US) and Certified Information Privacy Technologist (CIPT) by the International Association of Privacy Professionals.

Some of Mr. Rein’s publications include the following:

• “Ninth Circuit Limits CFAA To Digital “Breaking And Entering,” Finds LinkedIn Likely Has No CFAA Claim Against Web Scraper,” Goodwin Alert ,April 20, 2022)
• "Amgen v. Sanofi: The fall of the newly characterized antigen test (if it ever truly, jurisprudentially existed in the first place),” Journal of Generic Medicines, May 2019
• “Extraterritoriality and infringement of blockchain claims,” World Intellectual Property Review, September 3, 2018
• "Time To Remove Patent Barriers To US Drug Manufacturing,” Law360, August 6, 2018
• “Awkward Positions: Second Circuit Confronts Dueling Claims for Deference,” New York Law Journal, May 15, 2018
• “Stumbling Blocks: Proving Infringement of Blockchain Claims, Issues of Decentralisation and Extraterritoriality,” Intellectual Property Magazine, March 2018
• "Incentivizing Brand Pharma Cos. To Manufacture In The US,” Law360, June 29, 2017
• "Making America Manufacture Drugs Again,” Law360, March 2, 2017
• "Galderma Labs. v. Tolmar Inc.: Determining the contours of when a claimed concentration is obvious in view of a prior art range of concentrations,” Journal of Generic Medicines, December 2014
• "Pozen Inc. v. Par Pharmaceutical, Inc.: “Fuzzy” limitations and the doctrine of equivalents,” Journal of Generic Medicines, December 2013
• “The America Invents Act: Post Grant And Inter Partes Review In The Era Of Biosimilar Biological Products,” Update Magazine, March/April 2012
• "AstraZeneca v. Apotex: Section viii statement or approved label – a Hobson’s choice?,” Journal of Generic Medicines, October 2011
• “Healthcare Reform Creates Pathway for Biosimilar Biologics,” IP Frontline, April 9, 2010
• “A Discussion of Generic Drug Approval and Patent Systems in the United States and Canada,” Canadian Intellectual Property Review, June 2009
• "Abbott v Torpharm: The Contours of Contempt,” Journal of Generic Medicines, July 2008
• "Abraxis v Mayne: What You Say Can, and will, be Used against You,” Journal of Generic Medicines, April 2007
• "Purdue v Endo: ‘It Ain't Over Till It's over’,” Journal of Generic Medicines, April 2006

SPEAKING ENGAGEMENTS

Mr. Rein has moderated or spoken at various events, including those organized by the American Israel Public Affairs Committee, the Israeli chapter of AIPPI (Association Internationale pour la Protection de la Propriété Intellectuelle), the Food and Drug Law Institute, the Hebrew University Faculty of Law, the Intellectual Property Institute of Canada, the International Generic and Biosimilar Medicines Association, and the New York City Bar Association.